Loading...
Market
Outcome of First Regulatory Review for Regeneron-Mammoth CRISPR Therapy by 2026
5
Resolution / Starting Odds
Approval • 33%
Request for additional data • 33%
Rejection • 33%
FDA announcement or a similar regulatory body's public communication.
Story
Regeneron, Mammoth Launch $100M In Vivo CRISPR Collaboration for Multiple Diseases
Apr 25, 2024, 02:50 PM
Regeneron Pharmaceuticals has entered into a collaboration with Mammoth Biosciences to research, develop, and commercialize in vivo CRISPR-based gene editing therapies aimed at multiple diseases and tissues beyond the liver. The partnership involves a $100 million total upfront payment and equity investment by Regeneron, which includes $5 million upfront and a $95 million equity investment. This collaboration marks a significant expansion of Regeneron's efforts in genetic medicine, building on previous partnerships and acquisitions, including a longstanding research pact with Intellia Therapeutics for transthyretin amyloidosis and the purchase of a gene therapy biotech. The therapies will utilize Mammoth Biosciences’ ultracompact CRISPR and Regeneron's antibody-directed AAVs.
View original story
Similar markets
Yes, for one therapy • 40%
Yes, for more than one therapy • 20%
No • 40%
Below 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
Above 75% • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
Cancer • 20%
Rare genetic disorders • 20%
Heart disease • 20%
Neurological disorders • 20%
Other • 20%
In Vivo Therapy • 33%
Ex Vivo Therapy • 33%
Diagnostic Tool • 34%